GO
Loading...

GlaxoSmithKline PLC

More

  • GSK-linked investigator found guilty in China trial Friday, 8 Aug 2014 | 12:12 PM ET
    An internal court video shows British investigator Peter Humphrey arriving at a courtroom after a lunch break, during his trial at Shanghai No.1 Intermediate People's Court August 8, 2014.

    An investigator linked to the U.K. drug giant GSK was convicted in a case that many say highlights the risks of conducting due diligence in China.

  • NEW YORK, Aug 5- Belgian pharmaceutical company UCB is exploring a sale of its Kremers Urban Pharmaceuticals Inc division, a U.S. specialty generics business that could fetch as much as $2 billion, according to people familiar with the matter. Other companies that are exploring similar sales include GlaxoSmithKline Plc, Sanofi SA and Merck& Co Inc..

  • Midday movers: Amgen, Groupon, Walt Disney & more Monday, 4 Aug 2014 | 1:02 PM ET
    A live market monitor is viewed on the floor of the New York Stock Exchange (NYSE).

    Some of Monday's midday movers:

  • *Advair restored to Express Scripts 2015 formulary list. LONDON, Aug 4- GlaxoSmithKline received a boost on Monday from a decision by Express Scripts, the largest U.S. pharmacy benefit manager, to reinstate its top-selling lung drug Advair as an approved drug in 2015..

  • *Investors focused on possible Pfizer return. LONDON, July 31- AstraZeneca raised its sales and earnings forecasts for the year on Thursday, showing resilience after seeing off a $118 billion takeover approach from rival Pfizer two months ago.

  • LONDON, July 31- AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.

  • *FDA lists 10 violations at Taiwan plant. July 29- Impax Laboratories Inc said the U.S. Food and Drug Administration raised concerns about the company's factory in Taiwan, casting in doubt the future of its Parkinson's drug, rytary.

  • GSK chief floats break-up option Sunday, 27 Jul 2014 | 7:30 PM ET

    GSK's chief executive has opened the possibility of the group being broken up as he pushes through a sweeping overhaul of Britain's biggest drugmaker.

  • Europe backs new leukemia drugs from J&J and Gilead Friday, 25 Jul 2014 | 7:20 AM ET

    LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.

  • Allegations of GSK corruption spread to Syria Friday, 25 Jul 2014 | 1:35 AM ET

    GlaxoSmithKline faces new corruption allegations in Syria, where it has been accused of paying bribes to secure business.

  • EXCLUSIVE-Allegations of GSK corruption spread to Syria Thursday, 24 Jul 2014 | 1:19 PM ET

    LONDON, July 24- GlaxoSmithKline faces new allegations of corruption, this time in Syria, where the drugmaker and its distributor have been accused of paying bribes to secure business, according to a whistleblower's email reviewed by Reuters.

  • LONDON, July 24- GlaxoSmithKline said on Thursday it is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa.

  • GSK seeks approval for world's first malaria vaccine Thursday, 24 Jul 2014 | 6:00 AM ET

    LONDON, July 24- GlaxoSmithKline is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa.

  • Aced the SAT? Try this Cramer question Wednesday, 23 Jul 2014 | 6:19 PM ET

    If you have a penchant for quizzes and such, Jim Cramer thinks this question could lead you to a solid stock idea.

  • Midday movers: Caterpillar, EMC, Xoom & More Wednesday, 23 Jul 2014 | 1:12 PM ET

    Some of Wednesday's midday movers:

  • LONDON, July 23- Britain's fraud office is working with authorities in China in a first for such Anglo-Chinese cooperation as it carries out its own investigation into alleged corruption at drugmaker GlaxoSmithKline.

  • Europe closes higher despite Ukraine tensions Wednesday, 23 Jul 2014 | 11:31 AM ET

    European shares closed higher on Wednesday amid corporate earnings news and ongoing turmoil in Gaza and Ukraine.

  • LONDON, July 23- GlaxoSmithKline cut its 2014 earnings outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • Cramer: This stock could quadruple Wednesday, 23 Jul 2014 | 10:57 AM ET
    Jim Cramer

    Results of a clinical trial of a breast cancer drug could make this company a takeover target, too, says CNBC's Jim Cramer.

  • UPDATE 2-GSK warns on profits as weak lung drug sales hit Wednesday, 23 Jul 2014 | 9:12 AM ET

    LONDON, July 23- GlaxoSmithKline cut its 2014 earnings outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.